Avacopan 10mg capsules

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a dangerous autoimmune condition that usually requires high-dose glucocorticoids with immunosuppressive agents. Although effective, long-term glucocorticoid use is associated with significant toxicity. Avacopan, a selective inhibitor of C5a receptors, has emerged as a possible glucocorticoid-sparing drug for AAV, potentially offering a safer, more specific approach to treat the disease. This systematic review and meta-analysis aimed to compare the efficacy and safety of avacopan and conventional glucocorticoid-containing regimens for the treatment of AAV. A systematic search was conducted in PubMed, Embase, Scopus, and the Cochrane Library between 2000 and 2025. Post hoc subgroup analyses, randomized controlled trials, and observational reports that compared avacopan with glucocorticoid regimens in GPA or MPA patients were included. The primary outcomes were remission at week 26 and sustained remission at week 52. The secondary outcomes were relapse rates, renal outcomes, adverse events, glucocorticoid toxicity, and health-related quality of life. Nine studies with 2080 patients were combined. Compared with glucocorticoids, avacopan was associated with noninferior remission rates at week 26 and significantly higher sustained remission rates at week 52 (RR = 1.02, 95% CI: 0.88–1.19). It was associated with significantly reduced glucocorticoid toxicity, fewer adverse events, and improved quality of life scores. Heterogeneity was low (I2 = 5.4%), which supported the consistency of the results. Compared with standard glucocorticoid treatment, avacopan appears to offer a safer alternative with similar disease control and significantly reduced toxicity. These findings suggest a potential shift towards less toxic and more personalized approaches in AAV management, though further research is warranted to confirm these benefits. PROSPERO CRD420251033866. Not applicable.

Abstract licence: CC BY 4.0

BackgroundAvacopan, an oral C5a receptor antagonist, has been identified as a promising glucocorticoid-sparing agent in the management of ANCA-associated vasculitis (AAV). Although individual randomized controlled trials (RCTs) have indicated its therapeutic potential, there remains a need for comprehensive integration of efficacy and safety data to guide clinical decision-making.MethodsWe performed a meta-analysis of three pivotal RCTs-CLASSIC (n = 42), CLEAR (n = 67), and ADVOCATE (n = 331)-including a total of 440 individuals diagnosed with AAV. Primary endpoints encompassed clinical response, sustained and early remission rates, changes in renal function, as well as safety outcomes such as serious adverse events, infections, organ toxicity, hematologic complications, and glucocorticoid-related adverse effects. Summary effect estimates were derived using risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI). Study heterogeneity was quantified using the I² statistic and corresponding p-values.ResultsAvacopan was associated with efficacy outcomes that were equivalent to or exceeded those achieved with standard-of-care regimens. Clinical response (RR = 1.08; 95% CI: 0.98-1.19) and early remission (RR = 2.85; 95% CI: 0.95-8.54) favored avacopan. Improvements in renal parameters, including eGFR and renal response, were consistent but modest. Notably, avacopan substantially decreased glucocorticoid-related adverse events (RR = 0.78; 95% CI: 0.70-0.87; p ConclusionsAvacopan represents a highly effective and safer option compared to traditional glucocorticoid-based regimens for AAV. The capacity to sustain disease remission with reduced steroid-associated harm highlights its potential utility in evolving vasculitis treatment strategies.

Abstract licence: CC BY-NC 4.0

Abstract Background Avacopan is a novel C5a inhibitor that has shown promise in treating ANCA-associated vasculitis. We aimed to compare its therapeutic effects and efficacy with the current standard of care, which typically includes high-dose steroids and other immunosuppressive agents, such as cyclophosphamide, rituximab, and azathioprine. Methods We conducted a meta-analysis of randomized controlled trials that compared the therapeutic effects of avacopan with those of the standard of care. We selected three trials from five databases, including Cochrane, PubMed, Science Direct, Google Scholar, and ClinicalTrials.gov as of February 15, 2025. The primary outcomes were change in GFR, percent change in Urine Albumin Creatinine Ratio (UACR), and proportion of subjects achieving disease remission. The secondary outcome was the percent change in the Monocyte Chemoattractant Protein(MCP1)/creatinine ratio. The results are presented as mean differences for continuous variables or odds ratios for dichotomous variables. Results Three trials including 404 patients (204 avacopan, 200 standard care) were analyzed. Avacopan was associated with a significantly smaller reduction in proteinuria (mean difference in UACR change: 7; 95% CI: 5.75–8.25; pConclusion In conclusion, avacopan has beneficial steroid-sparing effects, but it may not be a viable alternative on its own. Further long-term studies are needed to better evaluate the efficacy and the risk of adverse effects associated with the use of avacopan in conjunction with low-dose steroid use.

Abstract licence: CC BY 4.0